#ESMO26 | postMONARCH – Final OS
After progression on CDK4/6i + ET, median OS with abemaciclib + fulvestrant was 32.1 vs 24.6 months, but statistical significance was not reached (HR 0.80; 95% CI 0.60–1.06; p=0.11).
The 7.5-month difference in median OS is noteworthy, but these results do not make this combination a preferred second-line option for me, given the availability of biomarker-directed therapies.
365 浏览 · 10 赞 · 3 转发 · 1 回复
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.org- Entisar saleh@Entisar_kilani
@dr_yakupergun Is there any comment on relation of benefit with duration of benefit on previous CDK4 6i? Thank you 🙏🏻
来源：Yakup Ergün · x.com